Stoke updates STK-001 Dravet data timelines: 45mg mid-2023, 70mg H2 2023; STK-002 ADOA Phase 1/2 start 2024

Stoke Therapeutics, Inc.

Multiple-dose STK-001 45mg data expected mid-2023; 70mg data expected second half 2023.
Phase 1/2a for Dravet syndrome to complete in 2023, enabling Phase 3 program in 2024.
STK-002 for ADOA: UK CTA submission expected H1 2023; Phase 1/2 start planned for 2024.
Updated corporate presentation posted ahead of J.P. Morgan Healthcare Conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.